These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 21980546)

  • 21. [Toxoplasmosis diagnosis in pregnancy: computer assisted follow-up interpretation of serologic tests].
    Nagy S; Hayde M; Panzenböck B; Adlassnig KP; Pollak A
    Wien Klin Wochenschr; 1997 Sep; 109(16):641-6. PubMed ID: 9412085
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for toxoplasmosis in pregnant women: presentation of a screening programme in the former "East"-Germany, and the present status in Germany.
    Hengst P
    Scand J Infect Dis Suppl; 1992; 84():38-42. PubMed ID: 1290072
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The program for antenatal screening of toxoplasmosis in Finland: a prospective cohort study.
    Koskiniemi M; Lappalainen M; Koskela P; Hedman K; Ammälä P; Hiilesmaa V; Teramo K
    Scand J Infect Dis Suppl; 1992; 84():70-4. PubMed ID: 1290079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Use of the ISAGA method in detection of specific IgM, IgA, IgE antibodies in acquired and congenital toxoplasmosis].
    Paul M
    Wiad Parazytol; 1997; 43(1):39-51. PubMed ID: 9289926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of socioeconomic factors on the efficiency of voluntary toxoplasmosis screening during pregnancy: a population-based study.
    Lange AE; Thyrian JR; Wetzka S; Flessa S; Hoffmann W; Zygmunt M; Fusch C; Lode HN; Heckmann M
    BMC Pregnancy Childbirth; 2016 Jul; 16(1):197. PubMed ID: 27473047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cost-benefit analysis of screening for congenital toxoplasmosis].
    Sagmeister M; Gessner U; Kind C; Horisberger B
    Schweiz Med Wochenschr Suppl; 1995; 65():103S-112S. PubMed ID: 7716447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of congenital toxoplasmosis in Szeged, Hungary.
    Szénási Z; Ozsvár Z; Nagy E; Jeszenszky M; Szabó J; Gellén J; Végh M; Verhofstede C
    Int J Epidemiol; 1997 Apr; 26(2):428-35. PubMed ID: 9169181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Congenital toxoplasmosis--prenatal aspects of Toxoplasma gondii infection.
    Rorman E; Zamir CS; Rilkis I; Ben-David H
    Reprod Toxicol; 2006 May; 21(4):458-72. PubMed ID: 16311017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systematic serologic screening for toxoplasmosis in pregnancy.
    Roos T; Martius J; Gross U; Schrod L
    Obstet Gynecol; 1993 Feb; 81(2):243-50. PubMed ID: 8423959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maternal serologic screening for toxoplasmosis.
    Pinard JA; Leslie NS; Irvine PJ
    J Midwifery Womens Health; 2003; 48(5):308-16; quiz 386. PubMed ID: 14526343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the possibilities for preventing congenital toxoplasmosis.
    Foulon W; Naessens A; Derde MP
    Am J Perinatol; 1994 Jan; 11(1):57-62. PubMed ID: 8155214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maternal and congenital toxoplasmosis in Mayotte: Prevalence, incidence and management.
    Kamus L; Belec S; Lambrecht L; Abasse S; Olivier S; Combe P; Bonnave PE; Vauloup-Fellous C
    PLoS Negl Trop Dis; 2023 Mar; 17(3):e0011198. PubMed ID: 36940228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Congenital toxoplasmosis in France in 2007: first results from a national surveillance system.
    Villena I; Ancelle T; Delmas C; Garcia P; Brezin AP; Thulliez P; Wallon M; King L; Goulet V;
    Euro Surveill; 2010 Jun; 15(25):. PubMed ID: 20587361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Knowledge-based computer-aided decision support in prenatal toxoplasmosis screening (TempToxopert).
    Boegl K; Anastassova N; Adlassnig KP; Rappelsberger A; Hayde M; Pollak A
    AMIA Annu Symp Proc; 2005; 2005():897. PubMed ID: 16779184
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cost-effectiveness of neonatal versus prenatal screening for congenital toxoplasmosis.
    Binquet C; Lejeune C; Seror V; Peyron F; Bertaux AC; Scemama O; Quantin C; Béjean S; Stillwaggon E; Wallon M
    PLoS One; 2019; 14(9):e0221709. PubMed ID: 31532766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Congenital toxoplasmosis following infection occurring late in pregnancy].
    Ben Abdallah R; Siala E; Maatoug R; Souissi O; Aoun K; Bouratbine A
    Arch Pediatr; 2011 Jul; 18(7):758-60. PubMed ID: 21632221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toxoplasmosis in pregnancy.
    Germann D; Matter L
    Lancet; 1994 Aug; 344(8921):540-1. PubMed ID: 7914630
    [No Abstract]   [Full Text] [Related]  

  • 38. Congenital toxoplasmosis.
    Hall SM
    BMJ; 1992 Aug; 305(6848):291-7. PubMed ID: 1392863
    [No Abstract]   [Full Text] [Related]  

  • 39. [Toxoplasmosis--epidemiology, clinical manifestation and infection in pregnant women].
    Biesiada G; Kalinowska-Nowak A; Czepiel J; Mach T
    Przegl Lek; 2006; 63(2):97-9. PubMed ID: 16969908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Periconceptional toxoplasmic seroconversion: about 79 cases].
    Garabedian C; Le Goarant J; Delhaes L; Rouland V; Vaast P; Valat AS; Subtil D; Houfflin-Debarge V
    J Gynecol Obstet Biol Reprod (Paris); 2012 Oct; 41(6):546-52. PubMed ID: 22542371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.